Last --
Change Today 0.00 / 0.00%
Volume 0.0
4568 On Other Exchanges
4568 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥131.0M
Compensation as of Fiscal Year 2014.

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company, Limited Announces Organizational Changes, Effective from April 1, 2015

Daiichi Sankyo Company, Limited announced the organizational changes taking place from April 1, 2015. Corporate Function: The current '4 Division Structure' shall change to a '3 Division Structure,' consisting of 'Corporate Strategy Division,' 'Corporate Management Division,' and 'General Affairs & Human Resources Division,' abolishing 'Legal Affairs & CSR Division,' with a view to developing comprehensive and consistent corporate strategies and ensuring smooth management of the Daiichi Sankyo Group. The 'Secretariat Department' and 'Internal Audit Department' are to be placed in direct report to the President & CEO as robust supporting functions to top management. The internal audit function of Daiichi Sankyo Healthcare Co. Ltd. is to be transferred to the 'Internal Audit Department' for unification of the Group's internal audit functions. Sales & Marketing Organization: 'Japan Company' is to be abolished for further reinforcement of the prescription pharmaceutical business and to enable swift decision-making and efficient management. The 'Sales & Marketing Division' is to be placed in direct report to the President & CEO and two Japan Company functions, 'Japan Business Management Department' and 'Business Intelligence Division,' are to be abolished. The functions of 'External Affairs Department,' 'Medical Affairs Department,' and 'Product Information Management Department,' which currently belong to 'Business Intelligence Division,' shall be transferred to the relevant divisions/departments. The current 16 sales branches are to be consolidated into 14 branches with a view to organizing a more efficient marketing structure. 'Kita Kanto Branch' and 'Koshinetsu Branch' shall be consolidated into a newly established 'Kanetsu Branch,' while 'Kyoto Branch' and 'Hokuriku Branch' shall be consolidated into a single 'Kyoto Branch'. Vaccine Business Organization: The operation of the 'Vaccine Business Strategy Department' is to be consolidated into Kitasato Daiichi Sankyo Vaccine Co. Ltd. with the aim of centralizing the management base, while the 'Vaccine Business Intelligence Division' and 'Vaccine Business Strategy Department' shall be abolished. A 'Vaccine Business Oversight Department,' which is in charge of external alliances and so on, shall be newly established. R&D Organization: The functions of project portfolio management shall be integrated into the 'Global Project Management Department,' which is in charge of R&D project management. The 'R&D Administration & Support Department' is to be renamed 'R&D General Affairs & Human Resources Department' and the 'Japan Development Oversight Function' is to be renamed 'Development Function'. Supply Chain Organization: The current functions of 'Supply Chain Planning Department' are to be divided into 'Supply Chain Planning Department' and 'Supply Chain Management Department.' The 'Supply Chain Planning Department' shall focus on planning and developing strategies for the whole Daiichi Sankyo Group's supply chain business. The supply and demand and production management function is to be transferred to a newly established 'Supply Chain Management Department.' The 'Supply Chain Technology Department,' 'Procurement Department,' and the production technology management of the supply chain functional companies (i.e. Daiichi Sankyo Propharma Co. Ltd. and Daiichi Sankyo Chemical Pharma Co. Ltd.) are to be merged in a newly established 'Supply Chain Technology & Procurement Department.' An 'Engineering Department' is to be established to consolidate the engineering functions, including coordination of facilities for production and investigational drugs, which are currently placed separately in the supply chain functional companies, the Pharmaceutical Technology Division, and Kitasato Daiichi Sankyo Vaccine Co. Ltd. Quality & Safety Management Organization: The functions of 'Pharmacovigilance Department' and 'Medical Affairs Department' are to be reorganized; newly established 'Safety and Risk Management Department' shall take over staff function and 'Pharmacovigilance Department' shall take over promotion function.

Daiichi Sankyo Company, Limited Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Daiichi Sankyo Company, Limited Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Daiichi Sankyo Company, Limited Announces Availability of SAVAYSA, New Anti-Coagulant in US

Daiichi Sankyo Company, Limited announced the availability of SAVAYSA, an oral anti-coagulant, in the US pharmacies. SAVAYSA was approved by the FDA on January 8, 2015 for the reduction in risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. According to the US label, SAVAYSA should not be used in NVAF patients with creatinine clearance (CrCL) levels greater than 95 mL/min because in that population there is an increased risk of ischemic stroke compared to warfarin. The approval of SAVAYSA in the US is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, the largest and longest single comparative global trials of a novel oral anticoagulant with NVAF or VTE, involving 21,105 and 8,292 patients, respectively. In ENGAGE AF-TIMI 48, SAVAYSA demonstrated significantly less major bleeding in patients with NVAF in the overall study population (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.70 to 0.91, p<0.001) and was non-inferior to warfarin for the primary efficacy endpoint of stroke or SE. In the indicated NVAF patient population in the US (patients with CrCL less than or equal to 95 mL/min), the rate of stroke and SE was 1.2% per year for SAVAYSA versus 1.8% per year for warfarin (HR, 0.68; 95% CI, 0.55 to 0.84). Consistent with the overall results, SAVAYSA also demonstrated fewer major bleeding events compared to warfarin in the indicated NVAF population, as well as lower rates of intracranial hemorrhage (0.5% per year for SAVAYSA and 1.0% per year for warfarin) and fatal bleeding (0.2% per year for SAVAYSA and 0.4% per year for warfarin), but higher rates of major GI bleeding (1.8% per year for SAVAYSA and 1.3% per year for warfarin). In Hokusai-VTE, SAVAYSA was shown to be non-inferior to warfarin for the primary endpoint of symptomatic recurrent VTE, with a significant 19% reduction in clinically relevant bleeding compared to warfarin (8.5% vs. 10.3%; HR, 0.81; 95% CI, 0.71 to 0.94, p=0.004) in patients with DVT or PE, following 5 to 10 days of initial therapy with a parenteral anticoagulant. The most common side effects observed in ENGAGE AF-TIMI 48 and Hokusai-VTE clinical trial participants were bleeding and anemia. SAVAYSA increases the risk of bleeding and can cause serious and potentially fatal bleeding.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,910.50 JPY +21.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $8.20 USD +0.24
BioCryst Pharmaceuticals Inc $10.28 USD +0.08
BioMerieux €96.56 EUR -0.76
Infinity Pharmaceuticals Inc $15.96 USD +0.76
Ipsen SA €45.96 EUR +0.56
View Industry Companies

Industry Analysis


Industry Average

Valuation 4568 Industry Range
Price/Earnings 14.5x
Price/Sales 1.2x
Price/Book 1.2x
Price/Cash Flow 14.6x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at